Vitro Biopharma Names Chris Furman Chief Executive Officer

July 18, 2022

Golden, Colorado, July 18, 2022 - Vitro Biopharma Inc. is pleased to announce Chris Furman as Chief Executive Officer and the newest member of the company’s Board of Directors.  

Chris Furman

Mr. Furman is a finance industry leader with more than 25 years’ experience in private and public capital markets. Chris has a proven track record of hiring and mentoring successful teams while also building strong and lasting relationships at the senior executive, C-Suite, and Board level. Prior to joining Vitro Biopharma, in his most recent role, Mr. Furman served as Managing Director at Virtus Investment Partners.

Chris has spent the last 25 years in various leadership roles, serving as Managing Partner at Forum Capital Advisors, a Managing Director at ArrowMark Partners, and a Managing Director at Janus Capital Group.

Dr. Caroline Mosessian, Chair of the Board of Directors, said: “We are delighted to announce Mr. Furman as Vitro Biopharma’s Chief Executive Officer. Chris brings an exceptional understanding of capital markets, driving enterprise value, and a wealth of experience from his various leadership roles over 25 years at Janus, Arrowmark Partners, Forum Capital and Virtus Capital. We have great trust and confidence that Chris is the leader who will guide Vitro Biopharma to its next level of excellence. The Board and entire executive team will support Chris as they work together to ensure a successful and exciting future for Vitro Biopharma.”

Mr. Furman commented: “This is an incredibly exciting time in the industry.  I am honored to be a part of the Vitro Biopharma team, lead their growth, and create shareholder value based on 25 years of research.”

The company’s former Chief Executive Officer, Dr. Jack Zamora, continues to be a director on the company’s Board of Directors and a significant company stockholder. 

About Vitro Biopharma

Vitro Biopharma is an innovative biotechnology company focused primarily in the field of regenerative medicine and cellular therapies, with ancillary focuses in the research services, cosmeceutical and nutraceutical fields.  With respect to our regenerative medicine business, we are leveraging our proprietary technologies to develop novel therapeutic candidates intended to address significant unmet medical needs in multiple disease areas with a focus on autoimmune disorders and inflammatory diseases.


Cautionary Note About Forward-Looking Statements
This press release contains “forward-looking statements” about the Company’s plan of business operations, product research and development activities, and other matters. Such forward-looking statements may be identified by words such as “intends,” “anticipates,” “believes,” “expects,” “hopes,” and other similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the marketplace, general economic conditions, receipt of additional working capital, and the overall state of the biotechnology industry. Most of these factors are outside our control.  You are cautioned not to put undue reliance on forward-looking statements.


Chris Furman
4621 Technology Drive
Golden, CO 80403
Phone: (1) 866–848-7267     
Source: Vitro Biopharma, Inc. 

Also in News

Pitt Hopkins FDA Trial
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat Pitt Hopkins Syndrome, a Rare Disease

November 18, 2021 0 Comments

Golden, Colorado-November 9, 2021- Vitro Biopharma, Inc. announced receipt of FDA authorization and clearance to enroll patients in its IND for a phase I-II, randomized, double-blind, placebo-controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in children with Pitt Hopkins Syndrome (PTHS), a rare neurogenetic disorder that features autistic traits. PTHS results from genetic mutations/deletions of a key brain development gene, TCF4 (transcription factor 4) that controls neurogenesis. 

Read More

Fitore and Infinivive logo
Vitro Biopharma Acquires Fitore Nutrition and Infinivive MD, Adding Revenues from Innovative Stem Cell Activation Products and Topical Cosmetic Stem Cell Serums

August 31, 2021 0 Comments

Golden, Colorado-August 31, 2021- Vitro Biopharma, Inc. ("Vitro') announced the acquisition of Fitore Nutrition ("Fitore") and Infinivive MD ("Infinivive"). Fitore, a private company headquartered in Denver, Colorado creates clinically validated supplements and sells them direct to consumers (D2C) via their unique digital marketing platform and SEO expertise.

Infinivive, located in Cherry Creek, Colorado developed the world's first topical cosmetic stem cell serum and is a nationally recognized company led by one of the top industry pioneers in the area of cosmetic surgery, Dr. Jack Zamora M.D.

Read More

Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group
Vitro Biopharma Signs Multi-Million Dollar Operating Service Contract with European Wellness Biomedical Group

August 20, 2021 0 Comments

Golden, Colorado-August 19, 2021-Vitro Biopharma, Inc. announced the signing of a contract with European Wellness Biomedical Group headquartered in Kuala Lumpur, Malaysia and it’s start-up subsidiary BioPep being registered in Delaware, USA to develop FDA-approval of biological products derived from existing mitochondrial peptide extracts now used globally as treatment of various conditions including aesthetic dermatology and skin revitalization, autism spectrum disorders, cardiovascular, metabolic and degenerative disorders, CKD and fertility through its global network of 12 (twelve) biomedical regenerative centers located throughout Europe and Asia Pacific. 

Read More